Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people

Shelby Sullivan, Elisa Fabbrini, Jay D. Horton, Kevin Korenblat, Bruce W. Patterson, Samuel Klein

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Obesity is associated with unfavorable alterations in plasma lipid concentrations. Data obtained from studies in cultured cells and rodent models show that Protein Convertase Subtilisn/Kexin 9 (PCSK9), a secreted protein that leads to degradation of LDL receptors in the liver, is an important regulator of plasma LDL cholesterol concentrations. Recent evidence suggests that PCSK9 may also regulate the very low density lipoprotein (VLDL) receptor expression and VLDL-triglyceride (TG) metabolism. The purpose of this study was to determine whether circulating PCSK9 concentrations are correlated with VLDL-triglyceride kinetics in obese people. Plasma PCSK9 concentration and VLDL-TG kinetics were evaluated in 39 nondiabetic, obese subjects (body mass index 36.9 ± 4.3 kg/m 2). Body composition was assessed by using dual-energy x-ray absorptiometry, and VLDL-TG kinetics were assessed by using stable isotopically labeled tracer infusion. We found that plasma PCSK9 concentrations correlated significantly with percent body fat (r = 0.322, P = 0.046) and serum LDL-cholesterol concentrations (r = 0.333, P = 0.036), but not with VLDL-TG secretion rate (r = 0.083, P = 0.614) or clearance rate (r = 0.032, P = 0.845). These data suggest that PCSK9 is likely involved in LDL-cholesterol metabolism, but it is not a clinically important regulator of VLDL kinetics in obese individuals.

Original languageEnglish (US)
Pages (from-to)302-306
Number of pages5
JournalTranslational Research
Volume158
Issue number5
DOIs
StatePublished - Nov 2011

Fingerprint

Lipoproteins
Blood Proteins
Kinetics
Liver
LDL Cholesterol
Proteins
Metabolism
Plasmas
VLDL Lipoproteins
LDL Receptors
Body Composition
Adipose Tissue
Cultured Cells
Rodentia
Body Mass Index
Obesity
Fats
Cells
X-Rays
very low density lipoprotein triglyceride

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, medical
  • Public Health, Environmental and Occupational Health

Cite this

Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people. / Sullivan, Shelby; Fabbrini, Elisa; Horton, Jay D.; Korenblat, Kevin; Patterson, Bruce W.; Klein, Samuel.

In: Translational Research, Vol. 158, No. 5, 11.2011, p. 302-306.

Research output: Contribution to journalArticle

Sullivan, Shelby ; Fabbrini, Elisa ; Horton, Jay D. ; Korenblat, Kevin ; Patterson, Bruce W. ; Klein, Samuel. / Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people. In: Translational Research. 2011 ; Vol. 158, No. 5. pp. 302-306.
@article{77f7cb38ac9e47198ea9f5640bdac6b9,
title = "Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people",
abstract = "Obesity is associated with unfavorable alterations in plasma lipid concentrations. Data obtained from studies in cultured cells and rodent models show that Protein Convertase Subtilisn/Kexin 9 (PCSK9), a secreted protein that leads to degradation of LDL receptors in the liver, is an important regulator of plasma LDL cholesterol concentrations. Recent evidence suggests that PCSK9 may also regulate the very low density lipoprotein (VLDL) receptor expression and VLDL-triglyceride (TG) metabolism. The purpose of this study was to determine whether circulating PCSK9 concentrations are correlated with VLDL-triglyceride kinetics in obese people. Plasma PCSK9 concentration and VLDL-TG kinetics were evaluated in 39 nondiabetic, obese subjects (body mass index 36.9 ± 4.3 kg/m 2). Body composition was assessed by using dual-energy x-ray absorptiometry, and VLDL-TG kinetics were assessed by using stable isotopically labeled tracer infusion. We found that plasma PCSK9 concentrations correlated significantly with percent body fat (r = 0.322, P = 0.046) and serum LDL-cholesterol concentrations (r = 0.333, P = 0.036), but not with VLDL-TG secretion rate (r = 0.083, P = 0.614) or clearance rate (r = 0.032, P = 0.845). These data suggest that PCSK9 is likely involved in LDL-cholesterol metabolism, but it is not a clinically important regulator of VLDL kinetics in obese individuals.",
author = "Shelby Sullivan and Elisa Fabbrini and Horton, {Jay D.} and Kevin Korenblat and Patterson, {Bruce W.} and Samuel Klein",
year = "2011",
month = "11",
doi = "10.1016/j.trsl.2011.06.006",
language = "English (US)",
volume = "158",
pages = "302--306",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people

AU - Sullivan, Shelby

AU - Fabbrini, Elisa

AU - Horton, Jay D.

AU - Korenblat, Kevin

AU - Patterson, Bruce W.

AU - Klein, Samuel

PY - 2011/11

Y1 - 2011/11

N2 - Obesity is associated with unfavorable alterations in plasma lipid concentrations. Data obtained from studies in cultured cells and rodent models show that Protein Convertase Subtilisn/Kexin 9 (PCSK9), a secreted protein that leads to degradation of LDL receptors in the liver, is an important regulator of plasma LDL cholesterol concentrations. Recent evidence suggests that PCSK9 may also regulate the very low density lipoprotein (VLDL) receptor expression and VLDL-triglyceride (TG) metabolism. The purpose of this study was to determine whether circulating PCSK9 concentrations are correlated with VLDL-triglyceride kinetics in obese people. Plasma PCSK9 concentration and VLDL-TG kinetics were evaluated in 39 nondiabetic, obese subjects (body mass index 36.9 ± 4.3 kg/m 2). Body composition was assessed by using dual-energy x-ray absorptiometry, and VLDL-TG kinetics were assessed by using stable isotopically labeled tracer infusion. We found that plasma PCSK9 concentrations correlated significantly with percent body fat (r = 0.322, P = 0.046) and serum LDL-cholesterol concentrations (r = 0.333, P = 0.036), but not with VLDL-TG secretion rate (r = 0.083, P = 0.614) or clearance rate (r = 0.032, P = 0.845). These data suggest that PCSK9 is likely involved in LDL-cholesterol metabolism, but it is not a clinically important regulator of VLDL kinetics in obese individuals.

AB - Obesity is associated with unfavorable alterations in plasma lipid concentrations. Data obtained from studies in cultured cells and rodent models show that Protein Convertase Subtilisn/Kexin 9 (PCSK9), a secreted protein that leads to degradation of LDL receptors in the liver, is an important regulator of plasma LDL cholesterol concentrations. Recent evidence suggests that PCSK9 may also regulate the very low density lipoprotein (VLDL) receptor expression and VLDL-triglyceride (TG) metabolism. The purpose of this study was to determine whether circulating PCSK9 concentrations are correlated with VLDL-triglyceride kinetics in obese people. Plasma PCSK9 concentration and VLDL-TG kinetics were evaluated in 39 nondiabetic, obese subjects (body mass index 36.9 ± 4.3 kg/m 2). Body composition was assessed by using dual-energy x-ray absorptiometry, and VLDL-TG kinetics were assessed by using stable isotopically labeled tracer infusion. We found that plasma PCSK9 concentrations correlated significantly with percent body fat (r = 0.322, P = 0.046) and serum LDL-cholesterol concentrations (r = 0.333, P = 0.036), but not with VLDL-TG secretion rate (r = 0.083, P = 0.614) or clearance rate (r = 0.032, P = 0.845). These data suggest that PCSK9 is likely involved in LDL-cholesterol metabolism, but it is not a clinically important regulator of VLDL kinetics in obese individuals.

UR - http://www.scopus.com/inward/record.url?scp=80054696614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054696614&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2011.06.006

DO - 10.1016/j.trsl.2011.06.006

M3 - Article

C2 - 22005270

AN - SCOPUS:80054696614

VL - 158

SP - 302

EP - 306

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 5

ER -